{"product_id":"sars-cov-2-vlp-ha-cov-2-wild-type-bhv20900008","title":"Severe Acute Respiratory Syndrome Corona Virus 2-like particles (Ha-CoV-2), Wild Type","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n.bhp-desc .bhp-cat-pill{display:inline-block;background:#003366;color:#fff;border-radius:20px;padding:3px 12px;font-size:13px;margin-bottom:10px}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n\u003ch2\u003eScientific Background\u003c\/h2\u003e\n\u003cp\u003eSARS-CoV-2, the causative agent of COVID-19, has evolved through numerous variants of concern (VOCs) and variants of interest (VOIs) since its emergence in late 2019. Each variant carries a distinct set of spike protein mutations that alter receptor binding affinity, immune evasion, and sensitivity to neutralizing antibodies. Accurate evaluation of antibody neutralization potency across these variants requires safe, reproducible pseudovirus tools that faithfully replicate the spike protein of each lineage.\u003c\/p\u003e\n\u003cp\u003eThe Hybrid Alpha-Pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a next-generation VLP platform developed by IBT Bioservices in collaboration with Virongy. Unlike conventional S-protein-only pseudotyped lentiviruses or rVSV vectors, Ha-CoV-2 incorporates all four SARS-CoV-2 structural proteins (S, M, N, and E), producing particles with native-like surface architecture. An alphavirus-derived self-replicating RNA vector drives rapid reporter expression (luciferase or fluorescent protein) within 6 hours of transduction — significantly faster than lentiviral systems.\u003c\/p\u003e\n\u003ch2\u003eProduct Description\u003c\/h2\u003e\n\u003cp\u003e\u003cspan class=\"bhp-cat-pill\"\u003eCoronavirus\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eThis Ha-CoV-2 VLP represents the \u003cstrong\u003eWild Type\u003c\/strong\u003e lineage. It is a single-cycle, BSL-2-compatible pseudovirus assembled from all four SARS-CoV-2 structural proteins with a reporter gene payload. Available with Firefly luciferase, GFP, or RFP reporter.\u003c\/p\u003e\n\u003ch2\u003eProduct Specifications\u003c\/h2\u003e\n\u003ctable class=\"bhp-spec-table\"\u003e\n\u003ctr\u003e\n\u003cth\u003eCatalog Number\u003c\/th\u003e\n\u003ctd\u003e0568-PP-001\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eFull Name\u003c\/th\u003e\n\u003ctd\u003eSARS-CoV-2 Virus-Like Particles (Ha-CoV-2), Wild Type\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eVariant\u003c\/th\u003e\n\u003ctd\u003eWild Type\u003c\/td\u003e\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\u003cth\u003eStructural Proteins\u003c\/th\u003e\n\u003ctd\u003eS (spike), M (membrane), N (nucleocapsid), E (envelope)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eReporter Payload\u003c\/th\u003e\n\u003ctd\u003eAlphavirus-derived self-replicating RNA encoding Firefly Luciferase, GFP, or RFP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eParticle Type\u003c\/th\u003e\n\u003ctd\u003eSingle-cycle alpha-pseudovirus (BSL-2 safe)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget Cells\u003c\/th\u003e\n\u003ctd\u003eACE2-expressing cells (e.g., Vero cells, HEK293T-ACE2)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSize Options\u003c\/th\u003e\n\u003ctd\u003e1X Concentrated: 25 × 200 µL (~100 wells per 96-well plate); 60X Concentrated: 5 × 100 µL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003e-80°C. Avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eApplications\u003c\/h2\u003e\n\u003cp\u003eHa-CoV-2 VLPs are validated for the following research applications:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eScreening and quantification of anti-SARS-CoV-2 neutralizing antibodies (IC50 determination)\u003c\/li\u003e\n\u003cli\u003eAnti-coronavirus small molecule drug screening\u003c\/li\u003e\n\u003cli\u003eQuantification of variant spike protein infectivity relative to Wild Type or other lineages\u003c\/li\u003e\n\u003cli\u003eIdentification of host co-factors and restriction factors for SARS-CoV-2 entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eAssay Protocol\u003c\/h2\u003e\n\u003cp\u003eA monolayer of Vero or ACE2-expressing cells is infected with Ha-CoV-2 VLPs or a VLP\/test-sample mixture for ~1 hr. Cells are overlaid with 1–2% FBS-supplemented media and incubated overnight at 37°C + 5% CO₂. Luciferase activity is measured at 6 hours post-transduction using Bright-Glo™ or Luciferase Assay System (Promega) on a plate reader. For fluorescent reporters (GFP\/RFP), reporter expression is quantified by fluorescence microscopy or flow cytometry. Neutralization is reported as % inhibition versus virus-only controls; IC50 is derived from dose-response curves.\u003c\/p\u003e\n\u003ch2\u003eSafety \u0026amp; Handling\u003c\/h2\u003e\n\u003cdiv class=\"bhp-warning-box\"\u003e\n\u003cstrong\u003eResearch Use Only (RUO).\u003c\/strong\u003e Single-cycle alpha-pseudovirus — BSL-2 containment required. Not approved for human or veterinary use. Commercial use requires written approval from Integrated BioTherapeutics, LLC. Repeated freeze-thaw cycles are not recommended as they may reduce viral titer and infectivity.\u003c\/div\u003e\n\u003c\/div\u003e","brand":"IBT Bioservices","offers":[{"title":"Luciferase \/ 60x Conc. 5 x 100uL","offer_id":53402776273261,"sku":"0568-PP-001-LUC-60X","price":1643.0,"currency_code":"USD","in_stock":true},{"title":"Luciferase \/ 1x Conc. 25 x 200uL (~100 wells)","offer_id":53402776306029,"sku":"0568-PP-001-LUC-1X","price":2591.0,"currency_code":"USD","in_stock":true},{"title":"GFP \/ 60x Conc. 5 x 100uL","offer_id":53402776338797,"sku":"0568-PP-001-GFP-60X","price":1643.0,"currency_code":"USD","in_stock":true},{"title":"GFP \/ 1x Conc. 25 x 200uL (~100 wells)","offer_id":53402776371565,"sku":"0568-PP-001-GFP-1X","price":2591.0,"currency_code":"USD","in_stock":true},{"title":"RFP \/ 60x Conc. 5 x 100uL","offer_id":53402776404333,"sku":"0568-PP-001-RFP-60X","price":1643.0,"currency_code":"USD","in_stock":true},{"title":"RFP \/ 1x Conc. 25 x 200uL (~100 wells)","offer_id":53402776437101,"sku":"0568-PP-001-RFP-1X","price":2591.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/0568-PP-001.png?v=1780510315","url":"https:\/\/www.ebiohippo.com\/products\/sars-cov-2-vlp-ha-cov-2-wild-type-bhv20900008","provider":"BioHippo","version":"1.0","type":"link"}